Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4196 trials
Conditions Type 2 Diabetes
Phase Not Applicable
Enrollment 3000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-05
Study Details Design, interventions, and primary outcomes

About This Study

CardioMET is an observational, multicenter, real-life registry, intending to collect data on patients with Type 2 Diabetes Mellitus, attending internal medicine and cardiology outpatient clinics. The aim of the registry is to characterize the cardiovascular risk profile and pharmacological management of Type 2 Diabetes Mellitus in Italy, in accordance with current ESC and AHA guidelines for primary and secondary prevention of CV disease.

Design

Study type: Observational Observational model: Cohort Time perspective: Other

Interventions / Regimen

  • Other: data collection — Data collection on diabetes therapy and follow-up

Primary Outcomes

  • Diabetes treatment adherence according to the most recent European Guidelines (12-24-36-48 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2022-10-01
Completion: 2027-10-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 3000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Federico II University
Contact Information
Study Contact:
Pasquale Perrone Filardi
+39081/746224
fpperron@unina.it
Pasquale Perrone Filardi
+39081/7462224
fpperron@unina.it
Federico II University of Naples, Department of Advanced Biomedical Sciences
Interventions
  • Other: data collection — Data collection on diabetes therapy and follow-up
Study Locations (1 sites)
Federico II University of Naples, Department of Advanced Biomedical Sciences, Naples, Napoli 80131 Italy
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years; * Diagnosis of type 2 diabetes mellitus (T2DM); * Stable clinical conditions * Outpatient settings * Ability to understand the study procedures and provide written informed consent. Exclusion Criteria: * Patients with type 1 diabetes mellitus; * Active participation in interventional studies; * Any condition that may put the patient at risk by participating in the study.
Conditions Type 2 Diabetes, Obesity, Semaglutide, G...
Phase Not Applicable
Enrollment 50
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-05
Study Details Design, interventions, and primary outcomes

About This Study

The aim of this study is to use advanced MRI scans to track changes in both muscle and fat in the body and heart over a 12-month period in individuals starting semaglutide. By doing so, we hope to gain a clearer understanding of how semaglutide affects muscle health and function. Our goal is to ensure the medication supports long-term well-being, particularly for people who may be at higher risk of muscle loss. This study involves (3) in-person study visits. At each visit, participants will be asked to: * Undergo magnetic resonance imaging (MRI) while resting and during exercise to take pictures of their heart, abdomen, and legs. * Complete tests to assess balance, sit-to-stand, walking speed, and handgrip strength. * Complete questionnaires related to demographics, health information, physical activity, and nutrition. * Have a blood sample collected from a vein in your arm. * Have your blood levels assessed through three finger pricks. * Complete three days of food records.

Design

Study type: Observational Observational model: Case Only Time perspective: Prospective

Primary Outcomes

  • Changes in skeletal and cardiac muscle mass (12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-05-15
Completion: 2028-04-30
Eligibility
Age: 18 Years – 80 Years
Sex: ALL
Volunteers: false
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Alberta
Contact Information
Study Contact:
Krista Jong, RD, BSc
780-492-9010
glimmer@ualberta.ca
Krista Jong
780-492-9010
glimmer@ualberta.ca
Mazankowski Alberta Heart Institute
Interventions
N/A
Study Locations (1 sites)
Mazankowski Alberta Heart Institute, Edmonton, Alberta T6G 0M9 Canada
Eligibility Criteria
Inclusion Criteria: * Adults 18-80 years of age * Starting semaglutide for type 2 diabetes or weight loss * Able to safely undergo an MRI scan (including meeting the physical requirements for MRI equipment) Exclusion Criteria: * Current use of semaglutide for more than 2 weeks * Major recent heart issues or other severe health conditions * Concerns related to MRI use (including magnetic implants, pacemaker, severe claustrophobia) * Dependence on a mobility aid (unable to participate in exercise MRI)
Conditions Type 2 Diabetes Mellitus (T2DM), Continu...
Phase NA
Enrollment 80
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-05
Study Details Design, interventions, and primary outcomes

About This Study

This clinical study explores whether adding technological tools during hospital discharge can help people with type 2 diabetes who are starting insulin therapy achieve better treatment adherence and blood glucose control once they return home. The discharge transition period includes both the final days of hospitalization and the first weeks to months after returning home. When people with type 2 diabetes are hospitalized, they sometimes need to begin insulin therapy. After discharge, managing insulin properly is essential to avoid high or low blood sugar levels. However, many patients forget or delay insulin doses, which can lead to poor control of their diabetes. This study will compare two groups of patients. All participants will be adults with type 2 diabetes, between 18 and 70 years old, who are newly starting insulin during their hospital stay. Group 1 ("technological group") will use a continuous glucose monitor (CGM) and a smart insulin pen cap called Insulclock. These tools show real-time blood glucose data and record when and how much insulin is injected. Patients and doctors can use this information to better adjust treatment. Insulclock also includes alarms to remind patients of their doses. Group 2 ("control group") will use the same devices, but they will not see the data in real time. Instead, they will manage their insulin based on standard finger-prick blood sugar checks four times a day, as typically done in standard care. Both groups will be followed for 12 weeks after hospital discharge. Medical check-ins will occur in weeks 1, 2, 4, 8, and 12. Blood tests and treatment adjustments will be performed as needed. The main goals are: To measure if the use of technology helps patients stick to their insulin schedule (fewer missed or mistimed injections). To see if it leads to better blood glucose control (e.g., more time within the recommended range, fewer episodes of low or high glucose). To evaluate patient satisfaction with this technology and check if the number of unplanned hospital readmissions decreases. The study will take place at Hospital Universitari i Politècnic La Fe in Valencia, Spain. Around 80 patients will participate. This study is important because real-world data about the use of CGM and smart insulin devices during the hospital-to-home transition are limited. It may help improve diabetes care for people starting insulin after hospitalization.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: Usual Care group — Participants will use the same CGM and Insulclock® devices, but in blinded mode (no data available to the patient). Insulin therapy will be adjusted using capillary blood glucose measurements (4 times daily). Device data will be collected retrospectively but not used for treatment decisions.
  • Device: Technological group — Participants will use a real-time continuous glucose monitoring device (e.g., FreeStyle Libre 2) and the Insulclock® smart insulin pen cap. Both devices provide real-time feedback and data on insulin administration and glucose levels. Patients will adjust their insulin therapy based on these data.

Primary Outcomes

  • Therapeutic adherence (From baseline (hospital discharge) to 12 weeks post-discharge)
  • Time in Range (From baseline (hospital discharge) to 12 weeks post-discharge)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-08-01
Completion: 2026-07
Eligibility
Age: 18 Years – 70 Years
Sex: ALL
Volunteers: false
Enrollment: 80 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Instituto de Investigacion Sanitaria La Fe
Principal Investigators:
  • JUAN FRANCISCO MERINO TORRES, Medicine (PRINCIPAL_INVESTIGATOR) - IIS La Fe
  • DARIO LARA GALVEZ, Medicine (STUDY_CHAIR) - IIS La Fe
  • MATILDE RUBIO ALMANZA, Medicine (STUDY_CHAIR) - IIS La Fe
Contact Information
Study Contact:
JUAN FRANCISCO MERINO TORRES, MEDICINE
+34617951330
merino_jfr@gva.es
DARIO LARA GALVEZ, Medicine
+34618205199
dario.galvez@hotmail.com
DARIO LARA GALVEZ, Medicine
+34618205199
dario.galvez@hotmail.com
Hospital La Fe, Valencia
Interventions
  • Device: Usual Care group — Participants will use the same CGM and Insulclock® devices, but in blinded mode (no data available to the patient). Insulin therapy will be adjusted using capillary blood glucose measurements (4 times daily). Device data will be collected retrospectively but not used for treatment decisions.
  • Device: Technological group — Participants will use a real-time continuous glucose monitoring device (e.g., FreeStyle Libre 2) and the Insulclock® smart insulin pen cap. Both devices provide real-time feedback and data on insulin administration and glucose levels. Patients will adjust their insulin therapy based on these data.
Study Locations (1 sites)
Hospital La Fe, Valencia, Valencia, Valencia 46026 Spain
Eligibility Criteria
Inclusion Criteria: * Adults aged 18 to 70 years. * Hospitalized patients with a diagnosis of type 2 diabetes mellitus (T2DM), either newly diagnosed during admission or previously known but not previously treated with insulin. * Initiation of insulin therapy (basal, basal-plus, or basal-bolus regimen) during hospitalization, with planned continuation post-discharge. * Independent in basic activities of daily living. * Adequate cognitive and functional capacity to manage the required devices: insulin pen, glucometer, continuous glucose monitoring (CGM) sensor, and Insulclock® cap. Exclusion Criteria: * Dependence in basic activities of daily living. * Any medical condition or functional limitation precluding the use of the CGM or the Insulclock® system. * Pregnancy or intention to become pregnant. * Diagnosis of type 1 diabetes mellitus. * Patients undergoing dialysis.
Conditions Type2 Diabetes Mellitus, Chronic Kidney ...
Phase PHASE1
Enrollment 120
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-05
Study Details Design, interventions, and primary outcomes

About This Study

To investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple oral doses of ONO-3310 in healthy Japanese adult male subjects and chronic kidney disease patients with type 2 diabetes mellitus

Design

Study type: Interventional Phases: Phase1 Allocation: Non Randomized Intervention model: Sequential Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: ONO-3310 — Single oral dose of ONO-3310 to HV
  • Drug: Placebo — Single oral dose of Placebo to HV
  • Drug: ONO-3310 — Multiple oral dose of ONO-3310 to HV
  • Drug: Placebo — Multiple oral dose of Placebo to HV
  • Drug: ONO-3310 — Single or multiple oral dose of ONO-3310 to CKD patients

Primary Outcomes

  • Adverse event (Through study completion, typically 10days (HV single), 23 days (HV multiple), and 74 days (CKD))
  • Maximum plasma observed concentration (Cmax) (Up to 10 days (HV single), 23 days (HV multiple), and 74 days (CKD))
  • Time to reach maximum observed concentration (Tmax) (Up to 10 days (HV single), 23 days (HV multiple), and 74 days (CKD))
  • Area under the plasma concentration versus time curve from time zero to 24 hours (AUC24h) (Up to 10 days (HV single), 23 days (HV multiple), and 74 days (CKD))
  • Area under the plasma concentration versus time curve from time zero to infinity (AUCinf) (Up to 10 days (HV single), 23 days (HV multiple), and 74 days (CKD))
  • Area under the plasma concentration versus time curve from time zero to time of last measurable concentration (AUClast) (Up to 10 days (HV single), 23 days (HV multiple), and 74 days (CKD))
  • Elimination half-life (T1/2) (Up to 10 days (HV single), 23 days (HV multiple), and 74 days (CKD))
  • Apparent total clearance (CL/F) (Up to 10 days (HV single), 23 days (HV multiple), and 74 days (CKD))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2026-06-02
Completion: 2027-11-30
Eligibility
Age: 18 Years – 64 Years
Sex: ALL
Volunteers: true
Enrollment: 120 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Ono Pharmaceutical Co., Ltd.
Principal Investigators:
  • Project Leader (STUDY_DIRECTOR) - Ono Pharmaceutical Co., Ltd.
Contact Information
Study Contact:
Ono Pharmaceutical Co., Ltd.
+18665877745
clinical_trial@ono-pharma.com
International Clinical Trial Support Desk
+17162141777
clinical_trial@ono-pharma.com
Interventions
  • Drug: ONO-3310 — Single oral dose of ONO-3310 to HV
  • Drug: Placebo — Single oral dose of Placebo to HV
  • Drug: ONO-3310 — Multiple oral dose of ONO-3310 to HV
  • Drug: Placebo — Multiple oral dose of Placebo to HV
  • Drug: ONO-3310 — Single or multiple oral dose of ONO-3310 to CKD patients
Study Locations (1 sites)
Souseikai Hakata Clinic, Fukuoka, Fukuoka Japan
Eligibility Criteria
Inclusion Criteria: Healthy adult part 1. Japanese healthy adult male subjects 2. Age at the time of informed consent: 18 to 45 3. BMI (at screening): 18.5 kg/m2 to less than 25.0 kg/m\^2 Chronic kidney disease patient part 1. Chronic kidney disease patients with type 2 diabetes mellitus 2. Age at the time of informed consent: 18 to less than 65 3. UACR measured by 24-hour urine collection: 300 mg/g to less than 3500 mg/g Exclusion Criteria: Healthy adult part 1. Subjects who currently receive treatment for or have a history of any of the following diseases: respiratory system, cardiovascular system, psychiatric system, nervous system, gastrointestinal system, immune system, liver, kidney, hematopoietic function, or endocrine function. 2. Presence or history of severe allergy to drugs or food 3. Presence or history of drug or alcohol dependence Chronic kidney disease patient part 1. Current symptoms of severe, progressive, or uncontrolled hepatic, hematologic, gastrointestinal, pulmonary, psychiatric, cardiac, endocrine, neurologic, or cerebral disease 2. Patients with type 1 diabetes mellitus 3. Patients with a history of dialysis treatment
Conditions Type 2 Diabetes
Phase NA
Enrollment 5950
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-05
Study Details Design, interventions, and primary outcomes

About This Study

Glycemic control is a mainstay of diabetes management to reduce the risk of microvascular complications and cardiovascular outcomes in people with type 2 diabetes (T2D). However, intensive control to near-normal glycated hemoglobin (HbA1c) yielded complex results in previous landmark trials. Potential risks of intensive glycemic control, such as hypoglycemia and weight gain, may partly contributed to the possible harms associated with this approach. Recent advances in diabetes management with development of newer antidiabetic drugs which minimize possible harms of intensive glycemic control as well as reduce cardiorenal risks enabled safer glycemic reduction. Thus, this randomized trial aims to evaluate the effects of near normalization of HbA1c with novel approaches on microvascular complications and cardiovascular outcomes in people with T2D.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: None

Interventions / Regimen

  • Drug: Dual-combination therapy — Group 1: Metformin/DPP-4i-based or Metformin/SGLT2i-based dual-combination therapy. Any oral antiglycemic drugs on the market.
  • Drug: Triple-combination therapy — Group 2: Metformin/SGLT2i/DPP-4i-based triple-cobmination therapy, or Group 3: Metformin/SGLT2i/Thiazolidinedione-based triple-cobmination therapy Any oral antiglycemic drugs on the market.
  • Device: Dexcom G7, Pasta — Real-time continous glucose monitoring system (CGMS) Device (sensor): Dexcom G7 Device (software): Kakaohealthcare Pasta Barozen Fit is also available.

Primary Outcomes

  • A composite of major adverse cardiovascular events (MACE) or diabetic microvascular events (6-month, 1-, 2-, 3-, 4-year after enrollment)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-11-21
Completion: 2029-09-30
Eligibility
Age: 19 Years and older
Sex: ALL
Volunteers: false
Enrollment: 5950 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Kyu Chang Won
Collaborators: Boryung Pharmaceutical Co., Ltd, Dong-A ST Co., Ltd., HK inno.N Corporation, Daewoong Pharmaceutical Co. LTD., Chong Kun Dang Pharmaceutical Corp., Celltrion, Kakao Healthcare Corp., Handok Inc.
Principal Investigators:
  • Kyu Chang Won, M.D., Ph.D. (PRINCIPAL_INVESTIGATOR) - Yeungnam University Hospital
Contact Information
Study Contact:
Kyu Chang Won, M.D., Ph.D.
+82-53-620-3846
kcwon63@gmail.com
Won, M.D., Ph.D.
+82-53-620-3846
kcwon63@gmail.com
Yeungnam University Medical Center
Kyu Chang Won, M.D., Ph.D.
Yeungnam University Medical Center
Interventions
  • Drug: Dual-combination therapy — Group 1: Metformin/DPP-4i-based or Metformin/SGLT2i-based dual-combination therapy. Any oral antiglycemic drugs on the market.
  • Drug: Triple-combination therapy — Group 2: Metformin/SGLT2i/DPP-4i-based triple-cobmination therapy, or Group 3: Metformin/SGLT2i/Thiazolidinedione-based triple-cobmination therapy Any oral antiglycemic drugs on the market.
  • Device: Dexcom G7, Pasta — Real-time continous glucose monitoring system (CGMS) Device (sensor): Dexcom G7 Device (software): Kakaohealthcare Pasta Barozen Fit is also available.
Study Locations (2 sites)
Yeungnam University Medical Center, Daegu, 42415 South Korea
Korea University Anam Hospital, Seoul, 02841 South Korea
Eligibility Criteria
Inclusion Criteria: 1. ≥19 years of age 2. Patient agreed to participate in the study and signed a written informed consent form 3. Type 2 diabetes (ADA criteria) 4. HbA1c≥7.0% and \<10.0% in patients receiving monotherapy, dual-combination therapy, or triple-combination therapy (when the submaximal dose was administered) with oral antidiabetic drugs (OADs) 5. Any of the following: A. Patients who one or more of the following conditions 1. Coronary artery disease 2. Atherosclerotic ischemic stroke, transient ischemic attack, carotid artery disease, peripheral artery disease, abdominal aortic aneurysm 3. Prevalence of diabetes ≥10 years 4. Left ventricular hypertrophy 5. Albuminuria 6. Chronic kidney disease (eGFR\<60mL/min/1.73m²) 7. Diabetic Retinopathy 8. Diabetic neuropathy or B. Patients who have two or more of the following cardiovascular risk factors (1) Family history of early-onset ASCVD (first-degree relatives with disease before age 55 for men and before age 65 for women) (2) Hypertension (on medication or with SBP≥140 mm Hg or DBP≥90 mm Hg) (3) Low HDL cholesterol concentration (\<40 mg/dL) (4) Current smoker (5) Obese (BMI≥25 kg/m²) Exclusion Criteria: 1. Type 1 diabetes 2. Estimated GFR\<45 ml/min/1.73m² 3. AST or ALT greater than 3 times the normal upper limit 4. Symptomatic heart failure (NYHA Class III or IV) 5. History of hospitalization for acute cardiovascular events within 3 months prior to the date of consent 6. Currently in active treatment for malignancy 7. Contraindications for each assigned drug, as applicable 8. Pregnant and nursing women 9. If the investigator determines that assignment to the standard glycemic control arm raises ethical concerns
Conditions Diabetes Mellitus, Type 2
Phase NA
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-05
Study Details Design, interventions, and primary outcomes

About This Study

The overarching goal of this explanatory mixed methods study is to evaluate how older people living with type 2 diabetes (T2D) integrate continuous glucose monitor (CGM) and activity data in diabetes self-management, and how this technology supports reduced sedentary behavior (SB) and improved glucose control.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Single Group Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Behavioral: SB Intervention — Self-monitoring and reminders about sedentary behavior

Primary Outcomes

  • Responsiveness to Fitbit 'stand' prompts (Day 10)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-05-12
Completion: 2027-10-31
Eligibility
Age: 55 Years and older
Sex: ALL
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Minnesota
Principal Investigators:
  • Mary Whipple, PhD, RN, PHN, FSVM, FAHA (PRINCIPAL_INVESTIGATOR) - University of Minnesota
Contact Information
Study Contact:
Mary Whipple, PhD, RN, PHN, FSVM, FAHA
612-626-5823
sittingresearch@umn.edu
Mary Whipple, PhD, RN, PHN, FSVM, FAHA
612-625-4470
whipp042@umn.edu
University of Minnesota
Interventions
  • Behavioral: SB Intervention — Self-monitoring and reminders about sedentary behavior
Study Locations (1 sites)
University of Minnesota, Minneapolis, Minnesota 55455 United States
Eligibility Criteria
Inclusion Criteria: * Aged 55 years and older * Self-reported T2D for ≥5 years * Speak and read English Exclusion Criteria: * Type 1 diabetes * Use of a CGM for ≥1 month in past 1 year * Not willing to use/wear the CGM, activPAL, or Fitbit * Dementia * Any of the following conditions that may impact SB: 1. Severe pulmonary disease 2. Severe osteoarthritis 3. Class III/IV heart failure 4. Require wheelchair or walker
Conditions Asthma
Phase PHASE3
Enrollment 150
Locations 50 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-04
Study Details Design, interventions, and primary outcomes

About This Study

Asthma is a chronic condition marked by narrowed and swollen airways due to inflammation leading to recurring symptoms that can vary and worsen unpredictably.\\xa0The purpose of this study is to assess how depemokimab, a monoclonal antibody, affects the structure and function of the lungs in asthmatic participants with type 2 inflammation, characterized by an eosinophilic phenotype.

Design

Study type: Interventional Phases: Phase3 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Biological: Depemokimab — Depemokimab will be administered.

Primary Outcomes

  • Mean Change from Baseline in Total Mucus Plug Volume Measured at Total Lung Capacity (TLC) at Week 26 (From Baseline up to Week 26)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2024-07-19
Completion: 2028-02-11
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 150 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: GlaxoSmithKline
Principal Investigators:
  • GSK Clinical Trials (STUDY_DIRECTOR) - GlaxoSmithKline
Contact Information
Study Contact:
US GSK Clinical Trials Call Center
877-379-3718
GSKClinicalSupportHD@gsk.com
EU GSK Clinical Trials Call Center
+44 (0) 20 89904466
GSKClinicalSupportHD@gsk.com
US GSK Clinical Trials Call Center
877-379-3718
GSKClinicalSupportHD@gsk.com
GSK Investigational Site
Interventions
  • Biological: Depemokimab — Depemokimab will be administered.
Study Locations (50 sites)
GSK Investigational Site, Brooksville, Florida 34613 United States
GSK Investigational Site, Plantation, Florida 33324 United States
GSK Investigational Site, Kansas City, Kansas 66160 United States
GSK Investigational Site, St Louis, Missouri 63110 United States
GSK Investigational Site, New Brunswick, New Jersey 08901 United States
GSK Investigational Site, New York, New York 10029 United States
GSK Investigational Site, DuBois, Pennsylvania 15801 United States
GSK Investigational Site, Philadelphia, Pennsylvania 19140-5103 United States
GSK Investigational Site, McKinney, Texas 75069 United States
GSK Investigational Site, Mechelen, 2800 Belgium
Eligibility Criteria
Inclusion Criteria: * Documented clinical diagnosis of asthma for greater than or equal to (\>=) 2 years as per the National Heart, Lung, and Blood Institute guidelines (NHLBI, 2020) or GINA guidelines (GINA, 2024), or joint guidance from the British Thoracic Society, National Institute for Health and Care Excellence, and Scottish Intercollegiate Guidelines Network \[NICE, 2024\] along with the following: an eosinophilic phenotype as evidenced by a blood eosinophil count of \>=300 cells/microliters (mcL) at screening or a documented history of blood eosinophil count \>=300 cells/mcL within 3 months prior to screening; Exhaled nitric oxide (FeNO) measure of \>=25 parts per billion (ppb) recorded at screening; and a previously confirmed history of \>= 2 exacerbations requiring treatment with systemic corticosteroid (SCS; intramuscular \[IM\], intravenous \[IV\], or oral), in the 12 months prior to screening, despite the use of medium to high dose Inhaled corticosteroids (ICS) * Uncontrolled asthma indicated by Astha Control Questionnaire-5 (ACQ-5) greater than (\>) 1.5 recorded at screening * Persistent airflow obstruction as indicated by pre-bronchodilator Forced Expiration Volume in 1 second (FEV1) less than (\<) 80 percentage (%) predicted (GLI 2012) and recorded at screening * A well-documented requirement for regular treatment with medium or high dose ICS (in the 12 months prior to screening with or without maintenance oral corticosteroids \[OCS\]) * Current treatment with at least one additional asthma controller medication, besides ICS, for at least 3 months \[for example, Long-acting Beta 2 agonists \[LABA\], Long-acting muscarinic antagonists \[LAMA\], leukotriene receptor antagonist (LTRA), or theophylline\] * Male Participants: No additional requirements for male participants * A female participant is eligible to participate if she is not pregnant or breastfeeding, and one of the following conditions applies: is a participant of non-childbearing potential (PONCBP) or is a participant of childbearing potential (POCBP) and using a contraceptive method that is highly effective (with a failure rate of \<1% per year), with low user dependency, * A POCBP must have a negative highly sensitive pregnancy test (urine or serum as required by local regulations) within 24 hours before the first dose of study intervention * Capable of giving written informed consent, * For the bronchoscopy sub study participants who sign the Informed Consent for the biopsy sub study, the following additional eligibility criteria will apply: * Participants not on maintenance OCS (oral corticosteroids) at the time of screening. * Participants with post bronchodilator FEV1 \>= 50% predicted * Participants with no known increased risk for bleeding or clotting abnormalities including: No history of easy bleeding, bruising or known bleeding diathesis; No current anticoagulant and antiplatelet therapy; No acetylsalicylic acid use within 2 weeks of the planned procedure; Normal screening platelet count * Participants with no specific contraindication to bronchoscopy with endobronchial biopsy in the opinion of the investigator * No history of allergic reaction to local anesthesia or general anesthetic agent, whichever is relevant to the procedure being performed Exclusion Criteria: * Presence of a known pre-existing, clinically important lung condition other than asthma. This includes (but is not limited to) current infection, bronchiectasis, pulmonary fibrosis, bronchopulmonary aspergillosis, or a history of lung cancer. Participants with current diagnoses of emphysema or chronic bronchitis (Chronic obstructive pulmonary disease \[COPD\] other than asthma) are excluded * Participants with other conditions that could lead to elevated eosinophils such as hyper eosinophilic syndromes including (but not limited to) Eosinophilic Granulomatosis with Polyangiitis (EGPA, formerly known as Churg-Strauss Syndrome) or eosinophilic esophagitis * Participants who developed an exacerbation within 4 weeks before screening * Participants with a known, pre-existing parasitic infestation within 6 months prior to screening unless treated and evidenced to have been resolved * A known immunodeficiency (e.g. human immunodeficiency virus HIV), other than that explained by the use of corticosteroids (CSs) taken as therapy for asthma * A current malignancy or previous history of cancer in remission for less than 12 months prior to screening * Participants who have known, pre-existing, clinically significant cardiac, endocrine, autoimmune, metabolic, neurological, psychiatric, renal, gastrointestinal, hepatic, hematologic abnormalities or any other system abnormalities that are uncontrolled with standard treatment * Participants with current diagnosis of vasculitis * Participants who have a previous documented failure with anti-IL-5/5R therapy * Participants who have received monoclonal antibody (mAb) therapy targeting IL 5/5R, IL 4R/IL 13, IL 33, IgE, or Thymic Stromal Lymphpoietin (TSLP) within 12 months or 5 terminal phase half-lives of the drug, whichever is longer prior to the screening. Authorized treatments for Coronavirus disease-2019 (COVID-19) are permitted * Participants who have received treatment with an investigational drug within the past 30 days or 5 terminal phase half-lives of the drug whichever is longer, prior to the first dose of study intervention (this also includes investigational formulations of marketed products) * Previously participated in any clinical study with biologic treatments for asthma (for example, omalizumab, mepolizumab, dupilumab, reslizumab, benralizumab, other mAbs (including Tezepelumab) or depemokimab and received study intervention (including placebo) within 12 months prior to the first dose of study intervention * A history (or suspected history) of alcohol misuse or substance abuse within 2 years prior to the first dose of study intervention * Current smokers or former smokers with a smoking history \>=20 pack years (number of pack years = \[number of cigarettes per day/20\] x number of years smoked) and vapers * Participants with allergy/intolerance to a mAb or biologic or any of the excipients of depemokimab * Participants who are pregnant or breastfeeding * Participants who have known evidence of lack of adherence to controller medications and/or ability to follow physician's recommendations * Participants who have occupational ionizing-radiation exposure exceeding 10 Millisievert (mSV) over 3 years as documented with a dosimeter; have been exposed to elevated ionizing radiation from research imaging studies, for example, Participation in a research study with a single positron emission tomography scan in the past 3 years, and Participation in a research study with 2 or more computed tomography (CT) scans in the past 3 years in the following anatomical regions: chest, abdomen, cardiac, or spine * Presence of metal objects that may interfere with chest CT quantification including presence of a cardiac pacemaker, defibrillator, metal prosthetic heart valve, metal projectile or metal weapon fragment (bullet, shrapnel, shotgun shot) or metal shoulder prosthesis * Evidence of clinically significant abnormality in the hematological, biochemical or urinalysis screen at screening (Visit 0), as judged by the investigator
Conditions Perennial Allergic Rhinitis Accompanied ...
Phase PHASE3
Enrollment 274
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-04
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to compare the efficacy and safety of DW1807 and DW1807-R2 in patients with perennial allergic rhinitis and comorbid asthma. The primary objective is to demonstrate the superiority of DW1807 over DW1807-R2 in improving the reflective total nasal symptom score (rTNSS) after 4 weeks of treatment.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Drug: Experimental — 1. DW1807 Once daily with water regardless of meals without chewing or crushing for up to 4 weeks 2. DW1807-R2 placebo Once daily with water regardless of meals without chewing or crushing for up to 4 weeks
  • Drug: Comparator — 1. DW1807 placebo Once daily with water regardless of meals without chewing or crushing for up to 4 weeks 2. DW1807-R2 Once daily with water regardless of meals without chewing or crushing for up to 4 weeks

Primary Outcomes

  • The mean change in reflective Total Nasal Symptom Score (rTNSS) (During the last 2 weeks of the treatment period (i.e., Weeks 3 to 4 of investigational product administration)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2024-09-09
Completion: 2026-09-18
Eligibility
Age: 19 Years and older
Sex: ALL
Volunteers: false
Enrollment: 274 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Daewon Pharmaceutical Co., Ltd.
Contact Information
Study Contact:
Jong-in Son
+82-2-2204-7053
jonginson112@daewonpharm.com
Interventions
  • Drug: Experimental — 1. DW1807 Once daily with water regardless of meals without chewing or crushing for up to 4 weeks 2. DW1807-R2 placebo Once daily with water regardless of meals without chewing or crushing for up to 4 weeks
  • Drug: Comparator — 1. DW1807 placebo Once daily with water regardless of meals without chewing or crushing for up to 4 weeks 2. DW1807-R2 Once daily with water regardless of meals without chewing or crushing for up to 4 weeks
Study Locations (1 sites)
Konkuk University Medical Center, Seoul, South Korea
Eligibility Criteria
Inclusion Criteria: \<Screening Visit\> 1. Male or female adults aged 19 years or older. 2. Individuals with a confirmed history or treatment record of perennial allergic rhinitis for at least 2 years at the time of screening. 3. Individuals who have a positive result on an allergy skin prick test or serum allergen-specific IgE antibody test (e.g., MAST or ImmunoCAP) conducted within 1 year prior to screening, and have a documented history of allergy to at least one perennial allergen (e.g., house dust mites, cats, dogs, molds, etc.). 4. Individuals diagnosed with asthma classified as Step 2 to Step 4. 5. Individuals who voluntarily provide written informed consent to participate in this clinical trial. \<Randomization Visit\> 1. Subjects who meet all of the following criteria based on self-assessed nasal symptom scores recorded in the subject diary during the 7-day run-in period. ① Performed nasal symptom evaluations twice daily (morning and evening) on at least 4 days during the run-in period. ② Had an average daily Reflective Total Nasal Symptom Score (rTNSS) of ≥6 (maximum score: 12). 2. Subjects with medication compliance of ≥80% during the 7-day run-in period. Exclusion Criteria: \<A. Disease and Medical History-Related Exclusion Criteria\> 1. Individuals diagnosed with non-allergic rhinitis of other causes. 2. Individuals with a documented acute exacerbation of asthma within 12 weeks prior to screening. 3. Individuals diagnosed with pulmonary diseases other than asthma. 4. Individuals diagnosed with the following types of sinusitis: ① Acute sinusitis within 4 weeks prior to screening. ② Clinically significant chronic sinusitis, as determined by the investigator. 5. Individuals with nasal polyps or other clinically significant nasal structural abnormalities. 6. Individuals who have undergone nasal or perinasal surgery within 12 weeks prior to screening. 7. Individuals with a documented upper respiratory tract infection (including the common cold) or systemic infection within 3 weeks prior to screening. \<B. Concomitant Medication Use\> 1. Subjects who have initiated immunotherapy or changed the dosage within 4 weeks prior to the screening visit. 2. Subjects who are on chronic use of medications that, in the opinion of the investigator, may interfere with the assessment of the investigational product's efficacy (e.g., tricyclic antidepressants). 3. Subjects who are currently taking, or are expected to require during the study, any medications that are prohibited as per the protocol. \<C. Laboratory Criteria\> 1. Subjects with serum AST (GOT) or ALT (GPT) levels \> 2 × the upper limit of normal (ULN) based on screening test results. 2. Subjects with an estimated glomerular filtration rate (eGFR, calculated by CKD-EPI) \< 30 mL/min/1.73 m² based on screening test results.
Conditions Asthma Acute, Asthma Attack, Asthma Exac...
Phase PHASE2
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-04
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to learn if nebulized ketamine helps treat moderate to severe asthma attacks in adults in the emergency department. It will also learn about the safety of ketamine when inhaled through a nebulizer. The main questions it aims to answer are: * Does nebulized ketamine improve breathing more than standard treatment alone? * What side effects, if any, do participants experience after receiving nebulized ketamine? Researchers will compare nebulized ketamine to a placebo (a saltwater mist with no medication) to see how well it works and how safe it is. Participants will: * Receive either nebulized ketamine or a placebo mist, along with standard asthma treatment * Have their breathing checked before and after treatment using a peak flow meter * Be monitored for 60 minutes and have their symptoms, vital signs, and any side effects recorded

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: Nebulized ketamine (0.5 mg/kg in normal saline to a total volume of 5ml) plus standard asthma excaerbationcare — \*\*Intervention Description:\*\* Nebulized ketamine is administered as a single dose of 0.5 mg/kg of ketamine hydrochloride diluted in 0.9% normal saline to a total volume of 5ml. The solution is delivered via a standard jet nebulizer over approximately 15-20minutes. This intervention is given once at the time of enrollment in the emergency department, in addition to standard asthma care. The ketamine used is in injectable solution form (typically 50 mg/mL concentration), drawn and diluted immediately prior to nebulization. Participants are monitored continuously for 60 minutes after administration to assess changes in peak expiratory flow rate (PEFR), symptom relief, and adverse events. The goal is to evaluate the bronchodilatory effect and safety of nebulized ketamine in adults with moderate to severe asthma exacerbation who present to the emergency department.
  • Drug: Placebo nebulization (5 mL normal saline) plus standard asthma care — \*\*Intervention Description (Control Group):\*\* Participants in the control group will receive a single nebulized dose of 5 mL of 0.9% normal saline, delivered using a standard jet nebulizer over approximately 10-15 minutes. This placebo intervention is administered once at the time of enrollment in the emergency department, after standard asthma care. Standard care includes repeated doses of nebulized salbutamol and ipratropium, systemic corticosteroids (oral or intravenous), and supplemental oxygen as needed. The placebo solution is identical in appearance and volume to the active ketamine solution used in the intervention group to maintain blinding. All participants will be monitored for 60 minutes after nebulization to assess changes in peak expiratory flow rate (PEFR), symptom relief using a visual analog scale (VAS), and the occurrence of any adverse events.

Primary Outcomes

  • Change in Peak Expiratory Flow Rate (PEFR) from baseline to 60 minutes post-intervention (Baseline (0 minutes) and 60 minutes post-intervention)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2026-05-30
Completion: 2029-08-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Oman Medical Speciality Board
Contact Information
Study Contact:
Awatif Al Alawi, M.D
+96893645233
Kotk606@gmail.com
Sultan Qaboos University Hospital
Awatif Al Alawi, M.D
Sultan Qaboos University Hospital
Interventions
  • Drug: Nebulized ketamine (0.5 mg/kg in normal saline to a total volume of 5ml) plus standard asthma excaerbationcare — \*\*Intervention Description:\*\* Nebulized ketamine is administered as a single dose of 0.5 mg/kg of ketamine hydrochloride diluted in 0.9% normal saline to a total volume of 5ml. The solution is delivered via a standard jet nebulizer over approximately 15-20minutes. This intervention is given once at the time of enrollment in the emergency department, in addition to standard asthma care. The ketamine used is in injectable solution form (typically 50 mg/mL concentration), drawn and diluted immediately prior to nebulization. Participants are monitored continuously for 60 minutes after administration to assess changes in peak expiratory flow rate (PEFR), symptom relief, and adverse events. The goal is to evaluate the bronchodilatory effect and safety of nebulized ketamine in adults with moderate to severe asthma exacerbation who present to the emergency department.
  • Drug: Placebo nebulization (5 mL normal saline) plus standard asthma care — \*\*Intervention Description (Control Group):\*\* Participants in the control group will receive a single nebulized dose of 5 mL of 0.9% normal saline, delivered using a standard jet nebulizer over approximately 10-15 minutes. This placebo intervention is administered once at the time of enrollment in the emergency department, after standard asthma care. Standard care includes repeated doses of nebulized salbutamol and ipratropium, systemic corticosteroids (oral or intravenous), and supplemental oxygen as needed. The placebo solution is identical in appearance and volume to the active ketamine solution used in the intervention group to maintain blinding. All participants will be monitored for 60 minutes after nebulization to assess changes in peak expiratory flow rate (PEFR), symptom relief using a visual analog scale (VAS), and the occurrence of any adverse events.
Study Locations (1 sites)
Sultan Qaboos University Hospital, Muscat, Alkhoudh PO Box 35 Oman
Eligibility Criteria
Inclusion Criteria: 1. Adults aged 18 years or older presenting to the Emergency Department with a clinical diagnosis of moderate to severe asthma exacerbation based on SIGN (Scottish Intercollegiate Guidelines Network) criteria. 2. PEFR between 33% and 75% of predicted value or personal best, as measured using a peak flow meter. 3. Stable vital signs as deemed by the treating physician 4. Alert and oriented, able to understand the study purpose and provide informed consent. 5. Not requiring immediate advanced airway intervention, including intubation or emergency non-invasive ventilation. Exclusion Criteria: 1. Known hypersensitivity or allergy to ketamine or any component of the nebulized solution. 2. History of psychosis, schizophrenia, or other severe uncontrolled psychiatric disorders. 3. Uncontrolled hypertension, defined as systolic BP \> 180 mmHg or diastolic BP \> 110 mmHg on two consecutive readings at least 5 minutes apart, despite initial ED management. 4. Hemodynamic instability, including persistent hypotension (SBP \< 90 mmHg) or tachyarrhythmias requiring urgent treatment. 5. Significant chronic lung disease, including: * COPD with frequent exacerbations or baseline FEV₁ \< 50% predicted * Interstitial lung disease (ILD) * Clinically significant bronchiectasis with baseline productive cough or infection 6. Pregnancy or currently breastfeeding. 7. Home BiPAP use or requirement for non-invasive ventilation (e.g., BiPAP/CPAP) during the ED visit (Note: isolated home CPAP for sleep apnea without daytime symptoms is acceptable). 8. Current intubation or imminent need for mechanical ventilation based on clinical judgment. 9. Severe cardiac disease, including decompensated heart failure, recent myocardial infarction (\<6 weeks), or known severe valvular disease. 10. Any other medical, surgical, or psychiatric condition that in the opinion of the investigator would place the patient at undue risk from study participation or interfere with the interpretation of study results.
Conditions Asthma Patients
Phase NA
Enrollment 36
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-04
Study Details Design, interventions, and primary outcomes

About This Study

The aim of the study; to determine the effect of the education program given to individuals diagnosed with asthma based on Roy's adjustment model on their psychosocial adjustment to the disease and their quality of life.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Asthma education program — An educational program based on the Roy Adaptation Model in addition to standard asthma treatment.

Primary Outcomes

  • "Evaluation of psychosocial adjustment of asthmatic individuals after education with the Psychosocial Adjustment To Illness-Self-Report Scale (PAIS-SR)". ("From enrollment to the end of treatment at 12 weeks")
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-12-20
Completion: 2025-10-01
Eligibility
Age: 18 Years – 64 Years
Sex: ALL
Volunteers: true
Enrollment: 36 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Nigde Omer Halisdemir University
Principal Investigators:
  • Dondu Erdogan Inan, MSc (PRINCIPAL_INVESTIGATOR) - Nigde Omer Halisdemir University
Contact Information
Study Contact:
Dondu Erdogan Inan, MSc
+903882112815
derdoganinan@ohu.edu.tr
Ulku Polat, PhD
+903122162903
ulku_gorgulu@yahoo.com
Interventions
  • Behavioral: Asthma education program — An educational program based on the Roy Adaptation Model in addition to standard asthma treatment.
Study Locations (1 sites)
Nigde Omer Halisdemir University, Niğde, Center 51100 Turkey (Türkiye)
Eligibility Criteria
Inclusion Criteria: * Being in the age range of 18-64 * Diagnosed with asthma for at least 6 months * To live in the city center * Asthma control test (ACT) score 24-20 (partial control) or ≤19 (uncontrolled) * Patients who voluntarily agreed to participate in the study Exclusion Criteria: * Has a secondary chronic disease other than asthma * Diagnosed with neuropsychiatric illness * Individuals with inability to understand or speak Turkish and sensory problems that prevent communication
Conditions Chronic Obstructive Pulmonary Disease (C...
Phase Not Applicable
Enrollment 600
Locations 10 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-04
Study Details Design, interventions, and primary outcomes

About This Study

As part of a post-approval commitment requested by the Ministry of Food and Drug Safety (MFDS), this open-label, single-arm, multicentre, observational Post-Marketing Surveillance (PMS) study aims to characterize the safety profile of Breztri in real-world clinical practice settings, either confirming known safety outcomes or identifying previously unsuspected adverse drug reactions. The study will also evaluate effectiveness of Breztri in real-world clinical practice settings, generating essential clinical evidence from a broader and more diverse Korean patient population representative of daily medical practice.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Incidence proportion of Adverse Events (AEs)/Adverse Drug Reactions (ADRs) (24 weeks)
  • Incidence proportion of Serious AEs (SAEs)/Serious ADRs (SADRs) (24 weeks)
  • Incidence proportion of Unexpected AEs/Unexpected ADRs (24 weeks)
  • Incidence proportion of Unexpected SAEs/Unexpected SADRs (24 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-09-17
Completion: 2027-07-31
Eligibility
Age: Not reported
Sex: ALL
Volunteers: false
Enrollment: 600 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: AstraZeneca
Contact Information
Study Contact:
AstraZeneca Clinical Study Information Center
1-877-240-9479
information.center@astrazeneca.com
Interventions
N/A
Study Locations (10 sites)
Research Site, Chuncheon, 24289 South Korea
Research Site, Daegu, 41931 South Korea
Research Site, Goyang-si, 10380 South Korea
Research Site, Gwangmyeong, 14353 South Korea
Research Site, Jinju, 52727 South Korea
Research Site, Seongnam-si, 13590 South Korea
Research Site, Seongnam-si, 13620 South Korea
Research Site, Seoul, 4401 South Korea
Research Site, Seoul, 6973 South Korea
Research Site, Wŏnju, 26426 South Korea
Eligibility Criteria
Inclusion Criteria: 1. Patients who have been diagnosed with COPD or asthma. 2. Patients who have newly initiated treatment with Breztri according to the approved label in Korea 3. Provision of signed and dated written informed consent by the patient or legally acceptable representative Exclusion Criteria: 1. Other off-label indications outside of the locally approved prescribing information 2. Pregnant and/or breast feeding 3. Current participation in any interventional trial
Conditions Asthma, COPD
Phase Not Applicable
Enrollment 310
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-04
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this observational study is to determine the prevalence of asthma and chronic obstructive pulmonary disease (COPD) among workers in an industrial zone in Thailand. The main question the study aims to answer is: What is the prevalence of asthma and COPD among workers in Thailand? Participants will complete a questionnaire on respiratory symptoms and undergo pulmonary function testing.

Design

Study type: Observational Observational model: Other Time perspective: Cross Sectional

Interventions / Regimen

  • Diagnostic Test: Pulmonary function test — Spirometry with bronchondilator test will be performed.

Primary Outcomes

  • Prevalence of asthma among workers at the Navanakorn Industrial Zone (Baseline)
  • Prevalence of COPD among workers in the Navanakorn Industrial Zone (Baseline)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-09-01
Completion: 2026-05-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 310 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Thammasat University
Principal Investigators:
  • Narongkorn Saiphoklang, MD (PRINCIPAL_INVESTIGATOR) - Thammasat University Faculty of Medicine
Contact Information
Study Contact:
Narongkorn Saiphoklang, MD
+6629269794
M_narongkorn@hotmail.com
Apiwat Pugongchai, MSc
+6629269142
pu.apiwat@gmail.com
Narongkorn Saiphoklang, MD
+6629269794
M_narongkorn@hotmail.com
Faculty of Medicine, Thammasat University
Interventions
  • Diagnostic Test: Pulmonary function test — Spirometry with bronchondilator test will be performed.
Study Locations (1 sites)
Faculty of Medicine, Thammasat University, Pathum Thani, Changwat Pathum Thani 12120 Thailand
Eligibility Criteria
Inclusion Criteria: * Age 18 years or older Exclusion Criteria: * Inability to perform spirometry